PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

COVID-19 has impacted psoriatic arthritis (PsA) patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use one of the QR codes below or search for it in the Google Play or App Store

Scan for Google Play Store Scan for Apple Store

This activity is one of four in this series, PsA+COVID-19: Innovations and Tools for Patient-Centered Psoriatic Arthritis Care.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Release Date: June 14, 2021
Expiration Date: June 14, 2022

Activity
Materials

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP

Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Richard Martin, MD, MA

Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan

David Kramer

Patient Presenter

 

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Use

Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.

Evaluate

Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA. 

Discuss

Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.

Inform

Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

 

 

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD 
  • Planner (Faculty): Linda Grinnell-Merrick, MS, NP-BC 
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C 

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB 
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer 
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB 

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi  
 

Activity Information

Target Audience
The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners 
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.
Provider number: 030803.
This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices. 

 

 

 

Provider
This activity is provided by Forefront Collaborative and AKH.

 

Commercial Support 
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Not Enrolled

Activity Includes

  • 7 Lessons
  • 9 Topics
  • 3 Quizzes